摘要
Abstract
Objective:To assess the effectiveness and safety of bevacizumab for ovarian cancer and explore the value of its clinical use. Methods:The database such as Medline、EM-base、PubMed、Cochrane Library、Web of Science、CNKI、CBM、VIP and WanFang Data were searched for randomized controlled trial(RCTs)from inception to Nov. 2013. And relevant mag-azine were also selected. Two reviewers independently screened literature according to the inclu-sion and exclusion criteria as well as the methods recommended by the Cochrane Handbook 5 . 0,extracted efficient data and assessed the methodological quality of the included studies. Then, the meta-analysis was performed using RevMan 5. 2 software. Results:A total of 5 RCTs invol-ving 4243 patients were included. The results showed that,there were significant difference in median progression free survival and no difference between the two groups in median overall survival. When taking safety into consideration bevacizumab can significantly increase the rate of hypertension(OR=3. 73,95%CI 2. 04 to 6. 82,P<0. 0001),proteinuria(OR=2. 96,95%CI 1. 13 to 7. 75,P=0. 03),bleeding(OR=4. 57,95%CI 3. 58 to 5. 84),P<0. 00001),compli-cation of wound healing (OR=1. 59,95%CI 1. 11 to 2. 28,P=0. 01)in this meta-analysis. But no significant difference was found in the incidence of gastrointestinal perforation,abscess and fistula,congestive heart failure,arterial and venous thromboembolic event and RPLS. Conclu-sion:Bevacizumab can obviously increase the incidence of adverse reaction of ovarian cancer, such as hypertension,proteinuria,bleeding,complication of wound healing. For the limitation of quality and quantity of included studies,this conclusion still needs to be proved by con-ducting more high quality researches.关键词
卵巢癌/贝伐单抗/随机对照试验/系统评价/Meta-分析Key words
Ovarian cancer/Bevacizumab/Randomized controlled trial/Systematic re-view/Meta-analysis分类
医药卫生
